BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/6/2024 9:51:00 AM | Browse: 379 | Download: 918
Publication Name World Journal of Hepatology
Manuscript ID 97295
Country Italy
ISSN 1948-5182 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Letter to the Editor
Article Title Rifaximin discontinuation during broad-spectrum antibiotic treatment in critically ill patients with hepatic encephalopathy
Manuscript Source Invited Manuscript
All Author List Lorenzo Ridola and Alessandro Mari
ORCID
Author(s) ORCID Number
Lorenzo Ridola http://orcid.org/0000-0002-8596-2609
Funding Agency and Grant Number
Corresponding Author Lorenzo Ridola, PhD, Associate Professor, Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Viale dell'Università 37, Rome 00185, Italy. lorenzo.ridola@uniroma1.it
Key Words Hepatic encephalopathy; Rifaximin discontinuation; Broad-spectrum antibiotics; Critically ill patients; Intensive care unit
Core Tip According to the current international guidelines, rifaximin administration is recommended only for the secondary prophylaxis of recurrent hepatic encephalopathy (HE). The rifaximin role for the treatment of an overt HE episode in inpatients is still unclear. However, in clinical practice, it is common to keep on rifaximin therapy that patients were already on prior to hospitalization during an overt HE episode. The Ward et al study demonstrated for the first time the feasibility and safety of rifaximin discontinuation during broad-spectrum antibiotic therapy, with significant cost saving during hospitalization.
Publish Date 2024-11-06 09:51
Citation

Ridola L, Mari A. Rifaximin discontinuation during broad-spectrum antibiotic treatment in critically ill patients with hepatic encephalopathy. World J Hepatol 2024; 16(11): 1356-1360

URL https://www.wjgnet.com/1948-5182/full/v16/i11/1356.htm
DOI https://dx.doi.org/10.4254/wjh.v16.i11.1356
Full Article (PDF) WJH-16-1356-with-cover.pdf